Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 21/01/2026 GMT			5-day change	1st Jan Change
5.710 ^USD	+4.01%		+1.78%	+0.71%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

Press Releases

01-08	MannKind Provides Business Updates and 2026 Growth Drivers	AQ
12-23	MannKind Shares FUROSCIX® Business Updates	AQ
12-01	MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease	AQ
11-11	MannKind to Present at the Jefferies Global Healthcare Conference	AQ
11-10	MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease	AQ
11-06	MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes	AQ
11-05	MannKind : Earnings Presentation (bd9d29)	PU
11-05	MannKind: Q3 Earnings Snapshot	AQ
11-05	MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
29/10/25	MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025	AQ
13/10/25	MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes	AQ
07/10/25	MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care	AQ
13/09/25	MannKind : Acquisition of scPharmaceuticals Presentation (a83ff3)	PU
27/08/25	MannKind to Present at Upcoming Investor Conferences	AQ
27/08/25	MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy	AQ
25/08/25	MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases	AQ
06/08/25	MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement	AQ
06/08/25	MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update	AQ
30/07/25	MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025	AQ
09/06/25	MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23	AQ
05/06/25	MannKind : Jefferies Global Healthcare Conference Presentation (1741b9)	PU
27/05/25	INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29	AQ
13/05/25	MannKind to Present at Upcoming Investor Conferences	AQ
08/05/25	MannKind: Q1 Earnings Snapshot	AQ
08/05/25	MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Biotechnology & Medical Research

Press Releases

Filters